Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11982016 | 0.89 | SMN1; SMN2 (0.34) | SMN1; SMN2HSD17B10CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL9682352 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2HSD17B10CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL11256982 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2HSD17B10CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL6729276 | 0.80 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL13290400 | 0.80 | KDM4E (0.39) | SMN1; SMN2HSD17B10ALDH1A1HTTL3MBTL1 | |
| SCHEMBL21813306 | 0.80 | CYP2D6 (0.37) | CYP2D6CYP2C19TYK2PDE4DPTGS1 | |
| SCHEMBL6730282 | 0.78 | ALDH1A1 (0.38) | SMN1; SMN2HSD17B10CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL14472418 | 0.78 | SMN1; SMN2 (0.36) | SMN1; SMN2HSD17B10ALDH1A1HTTL3MBTL1 | |
| SCHEMBL13882997 | 0.78 | ALDH1A1 (0.38) | SMN1; SMN2HSD17B10ALDH1A1HTTL3MBTL1 | |
| SCHEMBL18630868 | 0.78 | CYP2D6 (0.36) | SMN1; SMN2CYP2D6CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4339187-A1 | (HETERO)ARYLAMIDE COMPOUND AND PEST CONTROL AGENT | Nippon Soda Co., Ltd. (JP) | 2024-03-20 | — | — | EP | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230106002-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2022239798-A1 | (HETERO)ARYLAMIDE COMPOUND AND PEST CONTROL AGENT | 日本曹達株式会社 | 2022-11-17 | — | — | WO | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220056019-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2022-02-24 | — | — | US | disclosed |
| EP-3660013-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20220000844-A1 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220002272-A1 | BISARYL LACTAMS AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| US-11207323-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20130303510-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130137680-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
| US-20130109679-A1 | HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
| EP-2509980-A1 | HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE | Boehringer Ingelheim International GmbH (DE) | 2012-10-17 | — | — | EP | disclosed |
| EP-2509979-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | Boehringer Ingelheim International GmbH (DE) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071725-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20090227616-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION, A CORPORATION | 2009-09-10 | — | — | US | disclosed |
| US-20090048239-A1 | Therapeutic compounds | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227616-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | SMN1; SMN2 3299/4885HSD17B10 3705/4885CYP2D6 3974/4885 |
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | NR0B2, NR0B1, NR4A3 | SMN1; SMN2 974/4885HSD17B10 1537/4885CYP2D6 859/4885 |
| US-20230106002-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | SMN1; SMN2 1246/4885HSD17B10 1067/4885CYP2D6 2096/4885 |
| US-20220056019-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | SMN1; SMN2 4590/4885HSD17B10 308/4885CYP2D6 1529/4885 |
| US-20130109679-A1 | HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE | BRSK2, RPS6KA2, RPS6KB2 | SMN1; SMN2 1941/4885HSD17B10 1878/4885CYP2D6 3345/4885 |
| US-20220000844-A1 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | TRPV1, SCN7A, SCN1A | SMN1; SMN2 229/4885HSD17B10 2914/4885CYP2D6 1767/4885 |
| US-20090048239-A1 | Therapeutic compounds | RRP1B, RCE1, CTSZ | SMN1; SMN2 4013/4885HSD17B10 839/4885CYP2D6 203/4885 |
| US-11207323-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | SMN1; SMN2 1246/4885HSD17B10 1067/4885CYP2D6 2096/4885 |
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | SMN1; SMN2 3299/4885HSD17B10 3705/4885CYP2D6 3974/4885 |
| US-20130303510-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | SMN1; SMN2 334/4885HSD17B10 994/4885CYP2D6 4452/4885 |
| US-20130137680-A1 | HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE | PKD1, PAH, JAK2 | SMN1; SMN2 1330/4885HSD17B10 1894/4885CYP2D6 130/4885 |
| US-20220002272-A1 | BISARYL LACTAMS AS NRF2 ACTIVATORS | KEAP1, NFE2L2, NQO1 | SMN1; SMN2 4196/4885HSD17B10 645/4885CYP2D6 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.